Published in Women's Health Weekly, June 14th, 1999
A. Hasenburg, representing colleagues from the Freiburg University Medical Center, Germany, and the Baylor College of Medicine, Texas, presented data from a Phase I study of adenovirus-mediated herpes simplex virus-thymidine kinase (HSV-TK) suicide gene therapy combined with topotecan chemotherapy and surgery in ovarian cancer patients with recurrent disease at the 35th Annual Meeting of the American Society of Clinical Oncology, held May 15-18, 1999, in Atlanta, Georgia (abstract "Phase I Study of Adenovirus...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly